Table 4 Outcome differences between 2 year and 3 year.

From: An abluminal biodegradable polymer sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients undergoing coronary revascularization: 3-year clinical outcomes of a randomized non-inferiority trial

Events

Cordimax

Xience V

RR (95% CI)

P value

(n = 2460)

(n = 1237)

TLF

8 (0.3%)

17 (1.4%)

0.24 (0.10–0.55)

<0.001

All cause death

2 (0.1%)

2 (0.2%)

0.50 (0.07–3.57)

0.48

Cardiac death

2 (0.1%)

2 (0.2%)

0.50 (0.07–3.57)

0.48

MI

0 (0%)

2 (0.2%)

—

—

TLR (clinically driven)

6 (0.2%)

14 (1.1%)

0.22 (0.08–0.56)

<0.001

Death or MI

2 (0.1%)

4 (0.3%)

0.25 (0.05–1.37)

0.08

MACE

8 (0.3%)

17 (1.4%)

0.24 (0.10–0.55)

<0.001

  1. Values are n (%). *Relative risk (RR) and p values are from the chi-square test. MACE, Major Adverse Cardiovascular Event; MI, Myocardial Infarction; TLF, Target Lesion Failure; TLR, Target Lesion Revascularisation; and ST, Stent Thrombosis.
Back to article page